These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21595855)

  • 21. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
    Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
    Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL; Cheng MH; Tarng DC; Yang WC; Lee FK; Wang PH
    J Chin Med Assoc; 2013 Jul; 76(7):365-71. PubMed ID: 23664736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
    Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
    J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.
    Saito O; Saito T; Asakura S; Sugase T; Ito C; Ando Y; Muto S; Kusano E
    Clin Exp Nephrol; 2011 Feb; 15(1):126-31. PubMed ID: 21069410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raloxifene in the Treatment of Osteoporosis in Postmenopausal Women with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.
    Ma HY; Chen S; Lu LL; Gong W; Zhang AH
    Horm Metab Res; 2021 Nov; 53(11):730-737. PubMed ID: 34740274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.
    Adachi JD; Adami S; Kulkarni PM; Wong M; Stock JL
    J Clin Densitom; 2005; 8(3):273-7. PubMed ID: 16055956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast Growth Factor 21 Is Associated With Bone Mineral Density, but not With Bone Turnover Markers and Fractures in Chinese Postmenopausal Women.
    Hu W; He J; Fu W; Wang C; Yue H; Gu J; Zhang H; Zhang Z
    J Clin Densitom; 2019; 22(2):179-184. PubMed ID: 30228048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Shin CS
    Endocr J; 2005 Dec; 52(6):667-74. PubMed ID: 16410657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.
    Cosman F; Nieves JW; Zion M; Barbuto N; Lindsay R
    Osteoporos Int; 2008 Apr; 19(4):529-35. PubMed ID: 17929072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis.
    Majima T; Shimatsu A; Satoh N; Komatsu Y; Fukao A; Ninomiya K; Matsumura T; Nakao K
    J Bone Miner Metab; 2008; 26(2):178-84. PubMed ID: 18301975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.
    Genant HK; Lang T; Fuerst T; Pinette KV; Zhou C; Thiebaud D; Diez-Perez A
    Bone; 2004 Nov; 35(5):1164-8. PubMed ID: 15542042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.